Cargando…
Pharmacogenetics of new classes of antidiabetic drugs
Type 2 diabetes (T2D) has a continuously rising prevalence worldwide. Pharmacogenetics has been recognized as a promising concept for pharmacological treatment of T2D, as antidiabetic drugs are not equally effective and safe for all patients, and the costs of diabetes treatment are increasing. The l...
Autores principales: | Kadrić, Selma Imamović, Ćesić, Aida Kulo, Dujić, Tanja |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554705/ https://www.ncbi.nlm.nih.gov/pubmed/33974529 http://dx.doi.org/10.17305/bjbms.2021.5646 |
Ejemplares similares
-
Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
por: Dujic, Tanja, et al.
Publicado: (2021) -
Pharmacogenetics of Oral Antidiabetic Drugs
por: Becker, Matthijs L., et al.
Publicado: (2013) -
Pharmacogenetics and personalized treatment of type 2 diabetes
por: Semiz, Sabina, et al.
Publicado: (2013) -
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
por: Lo, Chris Wai Hang, et al.
Publicado: (2021) -
Gliptins: A New Class of Oral Antidiabetic Agents
por: Seshadri, K. G., et al.
Publicado: (2009)